ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0021

Shared Genetic Susceptibility Between Rheumatoid Arthritis and Bipolar Disorder: Analyses from Genome-Wide Association Studies

Jiayi Zheng1, Ruoning Ni2, Nevena Barjaktarovic3 and Yiming Luo4, 1The Wright Center for Graduate Medical Education, Scranton, PA, 2University of Iowa Hospitals and Clinics, Coralville, IA, 3The Wright Center for Community Health, South Abington Township, PA, 4Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) has been associated with bipolar disorder (BD) in epidemiological studies, including a recent Mendelian randomization analysis. This study aims to prioritize candidate genes that contribute to the shared genetic susceptibility between these two conditions, using data from genome-wide association studies (GWAS).

Methods: We obtained the summary statistics of the most recent GWAS in RA (PMID: 36333501, 22,350 cases and 74,823 controls) and BD (PMID: 34002096, 41,917 cases and 371,549 controls) of European ancestry. First, we performed linkage disequilibrium score regression (LDSC) to estimate the genetic correlation between the two conditions. We then conducted a cross-trait GWAS meta-analysis in RA and BD to identify shared genetic loci, using a fixed-effect model with METAL software. An additional analysis was carried out reversing the effect direction of BD to detect genetically associated loci with opposite effects. Next, we performed Bayesian genetic colocalization analysis between RA and BD in loci that were significant in the cross-trait GWAS meta-analysis (p < 5×10-8) to predict whether the shared genetic susceptibility was due to the same causal single-nucleotide polymorphisms (SNPs). To evaluate the functional consequences of the discovered signals, loci that were significant in cross-trait meta-analysis and predicted to share the causal SNPs (pp.H4 > 70%) were selected for colocalization with tissue-specific expression quantitative trait loci (eQTL) from the Genotype-Tissue Expression (GTEx), as well as plasma-based protein quantitative trait loci (pQTL) from the Atherosclerosis Risk in Communities (ARIC) dataset. We prioritized genes that colocalized with QTL signals of tissues relevant to RA and BD.

Results: Our analysis showed a modest negative genetic correlation between the two conditions (rg = – 0.1183, se = 0.0315, p = 0.0002). Two genomic loci, near rs112219496 (same effect direction, meta-analysis p = 1.35 x 10-10, pp.H4 = 91.2%) and rs1569723 (opposite effect direction, meta-analysis p-value = 2.22 x 10-13, pp.H4 = 98.9%), were significant in the cross-trait GWAS meta-analysis and colocalized between RA and BD (Table 1). The genomic locus near rs112219496 colocalized with pQTL and eQTLs for CILP2 in plasma, lung, and brain tissues. The genomic locus near rs1569723 colocalized with eQTLs for CD40 in the lung and brain tissues (Figure 1).

Conclusion: This study uncovers a complex relationship between the genetic susceptibilities of RA and BD. By implementing post-GWAS analyses, we identified CILP2 and CD40 as being associated with both RA and BD. Interestingly, CILP2 exhibited the same effect direction in both conditions, while CD40 demonstrated the opposite effect direction.

Supporting image 1

Table 1: Cross-trait meta-analysis of RA and BD and colocalization results of the regions +/- 500 kb of lead SNPs identified in cross-trait meta-analysis.

Supporting image 2

Figure 1: (A) LocusZoom plots of the region near rs112219496 with RA, BD, pQTL for HAPLN4 and eQTL for CILP2. (B) LocusZoom plots of the region near rs1569723 with RA, BD and eQTL for CD40. (C) Colocalization analysis with pQTLs and eQTLs across various tissues; each row represents a tissue, and each column denotes a gene. The color gradient from violet red to grey signifies the probability of GWAS loci and eQTLs sharing the same causal variant (PPH4).


Disclosures: J. Zheng: None; R. Ni: None; N. Barjaktarovic: None; Y. Luo: None.

To cite this abstract in AMA style:

Zheng J, Ni R, Barjaktarovic N, Luo Y. Shared Genetic Susceptibility Between Rheumatoid Arthritis and Bipolar Disorder: Analyses from Genome-Wide Association Studies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/shared-genetic-susceptibility-between-rheumatoid-arthritis-and-bipolar-disorder-analyses-from-genome-wide-association-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/shared-genetic-susceptibility-between-rheumatoid-arthritis-and-bipolar-disorder-analyses-from-genome-wide-association-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology